Category Archives: Health

What is new in the field of Health. Trending topics, and cutting edge research in the are of Health. Press Releases that give us updates on Health.

DuPont Nutrition & Biosciences Honors Dr. Sarkis Mazmanian for Human Microbiome Research


News Image

“Dr. Mazmanian’s extraordinary research has contributed significantly to our understanding of the human microbiome and the impact of gut microbes on neurological and immune systems.” said Sebastien Guery, global leader for Technology & Innovation, DuPont Nutrition & Biosciences.

The Danisco Foundation® has awarded the 2020 Danisco® Microbiome Science Award to Dr. Sarkis Mazmanian, Luis & Nelly Soux Professor of Microbiology in the Division of Biology and Biological Engineering at California Institute of Technology. Dr. Mazmanian has been selected for his research on the symbiotic relationship between bacterial species of the gut and the nervous and immune systems of their host.

Specifically, Dr. Mazmanian’s research focuses on the interaction between the gut microbiome and the brain and the impact of this gut-brain axis on diseases of the brain and overall immune system. His research has the potential to develop novel natural therapies to treat neurologic and immunologic disorders.

Dr. Mazmanian has received several awards and recognitions for his research including the Searle Scholar appointment in 2006, “Best Brains in Science under 40” by Discover Magazine in 2008, the MacArthur Foundation’s “Genius Grant” in 2012 and the “Science Dream Team” award from the Kavli Foundation in 2017.

Dr. Mazmanian will be formally honored at a virtual ceremony to be held on December 3, 2020 at which he will present some of his research to prominent scientists and leaders of DuPont Nutrition & Biosciences.

“Dr. Mazmanian’s extraordinary research has contributed significantly to our understanding of the human microbiome and the impact of gut microbes on neurological and immune systems. His unmatched scientific achievements represent a powerful advancement within in the fields of health, food and nutrition and we are delighted to honor his work with the Danisco® Microbiome Science Award”, said Sebastien Guery, global leader for Technology & Innovation, DuPont Nutrition & Biosciences.

The Danisco® Foundation itself was established in 1981 and provides funding and grants to support predominantly food science and research. The origins of the awards began in 2002 to help improve food products, notably industrially produced foods. With time and technological advancements, the scope has expanded to food, nutrition and health and today, the Danisco® Foundation Awards also encompass specific scientific achievements within the human microbiome space.

About DuPont™ Danisco®

DuPont™ Danisco® is the brand for a range of ingredients that help provide enhanced bioprotection, an improved nutritional profile, and better taste and texture with greater cost efficiency and lower environmental impact, meeting the needs of manufacturers of food and beverages, dietary supplements and pet food. Through the work of the global network of food scientists and technologists in DuPont, the Danisco® range is supported by a uniquely broad spectrum of know-how across applications and processing. http://www.danisco.com.

About DuPont Nutrition & Biosciences

DuPont Nutrition & Biosciences applies expert science to advance market-driven, healthy and sustainable solutions for the food, beverage, dietary supplement and pharmaceutical industries. We also use cutting-edge biotechnology across a range of markets to advance bio-based solutions to meet the needs of a growing population, while protecting our environment for future generations. We are innovative solvers who help our customers turn challenges into high-value business opportunities. For more information: http://www.dupontnutritionandbiosciences.com.

About DuPont

DuPont (NYSE: DD) is a global innovation leader with technology-based materials, ingredients and solutions that help transform industries and everyday life. Our employees apply diverse science and expertise to help customers advance their best ideas and deliver essential innovations in key markets including electronics, transportation, construction, water, health and wellness, food, and worker safety. More information can be found at http://www.dupont.com/. Investors can access information included on the Investor Relations section of the website at investors.dupont.com.

# # #

11/12/20

DuPont™, the DuPont Oval Logo, and all trademarks and service marks denoted with ™, SM or ® are owned by affiliates of DuPont de Nemours, Inc. unless otherwise noted.

Share article on social media or email:

Nipomo Dentist Reports ‘Options for Straightening Teeth’


dentist Nipomo

Today, there are many options for straightening teeth.

Every method has its place depending on the condition of the teeth and jaw.

Dr. Douglas Ng of Nipomo Family Dentistry reports that these days, there are many more options for straightening teeth than the dreaded metal braces. Kids and adults can benefit from the choices that include invisible aligners, lingual braces that are hidden behind the teeth, braces with ceramic parts, as well as the traditional metal braces.

Every method has its place depending on the condition of the teeth and jaw and the family dentist is the best professional to help determine when it is time to start teeth straightening treatments. Conditions such as crooked teeth, gaps between teeth, crowded teeth and more can contribute to increased risk for tooth decay and periodontal disease, speech problems and even jaw pain.

Sometimes, surgery to realign the jaws is needed along with an appropriate alignment method.

The options include:


  • Invisible aligners are clear, removable devices made of clear plastic trays that slip over the teeth and move them slightly towards their correct positions. The patient receives a new aligner approximately every two weeks and wears each new set for at least 22 hours a day. The devices are easy to remove, making it easier to stick to good brushing and flossing practices. Invisible aligners are gaining popularity with tweens and teens because they are nearly invisible and don’t subject the wearer to the embarrassment of a mouth full of “train tracks. Invisible aligners are also a less expensive option that braces, although children have been known to lose them because they are so easy to remove.
  • In 2015, around a million people in America were wearing braces. Today, over 4 million are wearing metal braces making them the most commonly used method for straightening teeth, especially severe problems and are the most inexpensive option. However, they can cause speech problems, irritate the mouth, and adjusting them can cause headaches. Plus, some foods are not recommended while wearing braces because they can bend or break the wires. Brushing and flossing take special attention.
  • Ceramic, tooth colored or clear versions of metal brackets, with tooth colored wires are also available. They are certainly less noticeable than wire braces and move teeth much faster than invisible aligners. However, they are much more expensive than metal braces and can stain if not properly cared for.
  • Lingual braces are placed behind the teeth and are less visible than the traditional metal braces. They can be quite uncomfortable and require a longer adjustment period. Speech can be affected and they can make the tongue sore form rubbing against the brackets and wires.
  • Surgery may be recommended when the jaw is not formed properly and may be causing a severe overbite, under bite, or crowding and may include an orthodontic treatment to straighten teeth after the jaw has healed.

Based on examinations and recommendations by the family dentist and orthodontist children can usually start orthodontic treatments between 8 and 10. In fact, age is rarely a limit to straightening teeth. Even senior citizens can benefit from the appropriate option.

The key is to continue good dental health practices and see your Nipomo family dentist on a regular basis. Discuss concerns about straighten teeth with your dentist and its never too early to open the discussion about your child’s teeth.

Dr. Ng’s services at Nipomo Family Dentistry include all aspects of general dentistry and pediatric dentistry, teeth whitening, veneers, and the popular Invisalign® clear aligner method. Dr. Ng has been providing California’s Central Coast families with quality dental care since 2008.

Nipomo Family Dentistry

195 N Thompson Ave Suite #3

Nipomo, CA 93444

(805) 929-1888

Share article on social media or email:

The Right Step Houston Celebrates 30 Years of Service in Harris County


The Right Step Houston staff stand in front of treatment center sign in celebration

The Right Step Houston Celebrates 30 Years of Service

We have learned so much in the last 30 years and have created an amazing foundation. But we don’t want to stop our growth here. We will continue to evolve to meet the needs of our clients and our community as we look toward the future.

The Right Step Houston, a long-time leader in addiction rehabilitation services, celebrated its 30th year in service to the Harris County community this month. While the anniversary would typically call for a gathering of alumni and community leaders, due to COVID-19, facility staff have pivoted these celebrations to create a safe way to honor the long standing treatment center.

Thirty years is an impressive amount of time for any treatment center, and The Right Step Houston has used this time to make positive connections within its surrounding communities. Throughout these years, The Right Step Houston has had the honor of impacting more than 21,150 clients. These clients have been provided the tools, motivation and support to find hope and healing outside of their substance abuse cycle. While COVID-19 has created barriers for celebrations, it has not affected The Right Step Houston’s mission: to create quality, affordable treatment for Texans.

“Our focus is really on what we do best and that is helping people heal,” remarked DeLisa Russell, Executive Director of The Right Step Houston. “And right now, we want to come together and help the community because there is an epidemic within this pandemic. Individuals are suffering at an overwhelming rate, with an increase especially in suicide and drug overdose. And while it is important to celebrate, we want to channel our celebration to focus on our community.”

Still, to honor this anniversary, The Right Step Houston will be erecting a memorial plaque within the treatment center along with a billboard advertisement in the Harris County area. The alumni will participate in 30 days of gratitude, where they will virtually share their recovery stories and their experience as Right Step Houston clients. And while the timeline remains unknown, there is hope that next year The Right Step Houston will host an in-person event to continue engaging with alumni, clients and the Harris County Community.

While this anniversary has set a precedent, it is important to remember that this is only a stepping stone for The Right Step Houston. By continuing to improve best treatment practices and strengthening community connections, The Right Step Houston can look forward to another strong 30 years ahead.

As DeLisa says, “We have learned so much in the last 30 years and have created an amazing foundation. But we don’t want to stop our growth here. We will continue to evolve to meet the needs of our clients and our community as we look toward the future.”

As The Right Step Houston celebrates its 30-year commitment to providing safe space for individuals to work through substance use disorders, Texans can feel supported knowing there is a trusted place to heal. For additional information regarding all the programs offered at The Right Step Houston, please contact 844.768.0169 or visit rightsteprehabhouston.com.

About Promises Behavioral Health

Promises Behavioral Health is a family of behavioral health programs with regional brands such as The Right Step, The Ranch and Promises. The company currently operates facilities across Texas, Tennessee, Florida, Pennsylvania and Massachusetts. Promises offers comprehensive, innovative treatment for substance abuse, sexual addiction, trauma, eating disorders and other mental health disorders. Through its programs, the company is committed to delivering clinically sophisticated treatment that promotes permanent lifestyle change, not only for the patient but for the entire family network. For more information, please visit http://www.PromisesBehavioralHealth.com.

Share article on social media or email:

Core Requirements, Expectations and Challenges Virtual Workshop Dec. 8, 2020


WCG FDAnews

WCG FDAnews

Data Integrity for GMP/Postmarket Professionals:

Core Requirements, Expectations and Challenges

A Virtual Workshop Presented FDAnews and Cerulean Associates LLC

Tuesday, Dec. 8 and Thursday, Dec. 10, 2020, 10:00 a.m.-4:30 p.m. EST

https://www.fdanews.com/dataintegrityforgmppmpros

Is the FDA’s increasing scrutiny on data integrity giving causing a data migraine? One must establish internal competency and assessment programs; otherwise, a Form 483 or warning letter can be expected.

With FDA data integrity requirements among the most stringent within regulated industries, compliance is challenging for drug and device manufacturers. This interactive virtual workshop makes it infinitely easier.

Data Integrity for GMP/Postmarket Professionals: Core Requirements, Expectations and Challenges will give attendees the tools needed to ensure electronic records are trustworthy and reliable across their entire data lifecycle, from initial data creation through long-term archives.

It will be led by award-winning FDA compliance expert, author and Cerulean Associates founder, John Avellanet. He can explain complex FDA data integrity regulations in simple “what to do, how to do it” language using real-world examples and offering practical advice you can follow. A former FDA and Department of Justice prosecutor calls Mr. Avellanet, “The best in the business. Period.” Confirm this for oneself when he shares:


  • How to apply the elements of data integrity characteristics — attributable, legible, contemporaneous, original and accurate (ALCOA+)
  • An exploration of overlooked guidance documents that can help define expectations (including what the FDA and the European Medicines Agency inspect for and why)
  • How to address recall handling and reporting and product complaint trending
  • How to deal with suppliers, including the typical supply chain red flags that FDA and other regulatory health agencies look for
  • What to take away from recent, relevant GMP and QSR data integrity enforcement examples
  • Considerations for both on-site and remote inspections, with questions and tactics one must be prepared to handle
  • The modern, risk-based validation techniques one needs to know, along with the FDA’s view of sampling, test cases and supplier-provided validations
  • The record-keeping “musts” to consider: which records to retain to prove good data integrity controls, incorporating quality audits and sampling techniques and developing a media migration strategy
  • The risks and realities of true and certified copies with digital records, from the basics of true/certified copy and legal admissibility to putting together a scanning process for manufacturing records and the true copy requirements from submission guidances

No more data migraines. By attending this virtual workshop attendees will be equipped to help the entire company stay compliant.

Multi-attendee discounts available!

Significant tuition discounts are available for teams of two or more from the same company.

Virtual Workshop Details:

Data Integrity for GMP/Postmarket Professionals:

Core Requirements, Expectations and Challenges

A Virtual Workshop Presented FDAnews and Cerulean Associates LLC

Tuesday, Dec. 8 and Thursday, Dec. 10, 2020, 10:00 a.m.-4:30 p.m. EST

https://www.fdanews.com/dataintegrityforgmppmpros

Tuition:

$597 per site

Easy Ways to Register:

Online: https://www.fdanews.com/dataintegrityforgmppmpros

By phone: 888.838.5578 or 703.538.7600

About FDAnews:

FDAnews is the premier provider of domestic and international regulatory, legislative, and business news and information for executives in industries regulated by the US FDA and the European Medicines Agency. Pharmaceutical and medical device professionals rely on FDAnews’ print and electronic newsletters, books and conferences to stay in compliance with international standards and the FDA’s complex and ever-changing regulations

Share article on social media or email:

SITC Announces Creation of Steven A. Rosenberg, MD, PhD, Endowed Scholars Fund Supporting Cancer Immunotherapy Research; Names Eric Tran, PhD, Inaugural Recipient


Society for Immunotherapy of Cancer

“Through his lab at the NCI, Dr. Rosenberg has engaged with hundreds of scientists, both young and old,” said SITC Vice President Patrick Hwu, MD, who worked with Dr. Rosenberg at the NIH. “He has focused on creating a whole new way to approach cancer through immune cells. His work is inspiring…”

The Society for Immunotherapy of Cancer (SITC) is pleased to announce the creation of the Steven A. Rosenberg, MD, PhD, Endowed Scholars Fund. Established in honor of Dr. Rosenberg, this fund recognizes his many contributions to the field by supporting investigators, who are emerging leaders in immuno-oncology, focused on a novel approach to advancing the field of cancer immunotherapy.

After completing surgical residency training in 1974, Dr. Rosenberg became the Chief of Surgery at the National Cancer Institute (NCI) at the National Institutes of Health (NIH)—a position he still holds today. As Chief of Surgery, he oversees an extensive clinical program to translate scientific advances into effective immunotherapies for patients with cancer.

“Through his lab at the NCI, Dr. Rosenberg has engaged with hundreds of scientists, both young and old,” said SITC Vice President Patrick Hwu, MD, who worked with Dr. Rosenberg at the NIH. “He has focused on creating a whole new way to approach cancer through immune cells. His work is inspiring a whole new generation of physician scientists to put the patient first, tackle the tough problems and never give up.”

Dr. Rosenberg has saved thousands of lives. His work pioneered the first effective immunotherapies and gene therapies for patients with advanced cancers and his studies of cell transfer immunotherapy have resulted in durable complete remission in patients with metastatic melanoma. He has also trained hundreds of cancer researchers, many of whom are leaders in the field of immunotherapy.

“In my years with Dr. Rosenberg at the NCI, I grew to appreciate not just his brilliant approach to science, but his wisdom and passion, which has shaped my career trajectory,” said Arie Belldegrun, MD. “The impact of his mentorship to hundreds of fellows and professors continues to ripple throughout the field of immunotherapy and beyond to help millions of patients. This scholarship paves the way for the next generation of scientists to be inspired by Dr. Rosenberg’s extraordinary legacy to find cures for cancer.”

Eric Tran, PhD (Earle A. Chiles Research Institute, a division of Providence Cancer Institute), was recognized as the inaugural recipient of the Dr. Steven A. Rosenberg Scholars Award for Cancer Immunotherapy Research at SITC’s 35th Anniversary Annual Meeting on Wednesday, Nov. 11.

His research award project, titled “Enhancing cellular therapy against cancer neoantigens”, contributed to a paradigm shift in basic immunology by definitively demonstrating that neoantigens arising from patient-specific somatic mutations are a major class of antigens being targeted by tumor-infiltrating T cells in most patients with epithelial cancers. His work was also the first to demonstrate that immunotherapy with neoantigen-specific CD4+ or CD8+ T cells could mediate the regression of metastatic human epithelial tumors, which helped usher in a new wave of cancer treatment by immunologically targeting cancer mutations. Learn more about Dr. Tran’s research.

Dr. Tran trained at the NCI with Dr. Rosenberg and has extensive experience in translational and clinical adoptive T-cell therapy against cancer and in evaluating the T-cell response against tumor neoantigens. Dr. Tran’s goal is to develop novel and more effective T-cell based immunotherapies for patients with cancer.

Each year, SITC will seek the best and brightest to continue Dr. Rosenberg’s legacy with research awards specifically for early career scientists focused on tackling challenges that face the field of cancer immunotherapy. Recipients will be picked through an abstract submission process and SITC’s Award Review Committee will serve as the selection committee.

About the Forward Fund

In 2012, SITC established the Forward Fund in to stimulate the future of science through the development and application of cancer immunotherapy. Since then, more than $4 million has been awarded by the Forward Fund to support early career scientists through research and education. Thanks to donors, hundreds of early career scientists’ careers have been shaped by the Forward Fund. By providing fellowships, young investigator awards and the one-of-a-kind SITC Sparkathon, SITC is inspiring the next generation, advancing the science and tackling the hurdles facing the field.

About SITC

Established in 1984, the Society for Immunotherapy of Cancer (SITC) is a nonprofit organization of medical professionals dedicated to improving cancer patient outcomes by advancing the development, science and application of cancer immunotherapy and tumor immunology. SITC is comprised of influential basic and translational scientists, practitioners, health care professionals, government leaders and industry professionals around the globe. Through educational initiatives that foster scientific exchange and collaboration among leaders in the field, SITC aims to one day make the word “cure” a reality for cancer patients everywhere. Learn more about SITC, our educational offerings and other resources at sitcancer.org and follow us on Twitter, LinkedIn, Facebook and YouTube.

Share article on social media or email:



Confluent Health Announces Partnership with Advanced and Preferred Physical Therapy


News Image

Commitment to quality and providing the best opportunities for staff to learn and grow, are integral to Confluent Health’s way of doing business. That’s why this partnership was forged.– David Todd, Founder/President of Advanced and Preferred Physical Therapy

Confluent Health is proud to announce its newest partnership with Advanced Physical Therapy and Preferred Physical Therapy, a therapist and employee-owned outpatient physical therapy practice with 29 locations throughout Kansas and Missouri.

“Since Advanced and Preferred Physical Therapy was founded in 2004, we have remained committed to building relationships for life. To us, providing top-notch, quality patient care to everyone who walks through our doors is more than a motto, it’s part of our culture,” said Founder and President, David Todd, PT. “That commitment to quality and providing the best opportunities for staff to learn and grow, are integral to Confluent Health’s way of doing business. That’s why this partnership was forged. We are so excited to continue to grow with Confluent Health in the communities we serve.”

The agreement, effective immediately, maintains Advanced and Preferred Physical Therapy brand while allowing them access to Confluent Health’s shared management services, including accounting and finance, talent acquisition, marketing, and staff development opportunities. Through Confluent Health, Advanced and Preferred Physical Therapy clinicians will also have greater access to Evidence In Motion’s nationally recognized physical therapy education programs and the financial support to fuel further expansion across the region.

“This partnership is founded on strong leadership from David and the Advanced and Preferred Physical Therapy team. We are looking forward to bringing such an outstanding group of clinicians into the Confluent Family,” said Confluent Health President and CEO Larry Benz, PT, DPT, OCS, MBA, MAPP. “Further, Confluent Health’s unique ownership model will be welcoming 26 local Advanced and Preferred employees and physical therapists into the partnership as owners.”

Combining Confluent Health’s shared management services with Advanced and Preferred Physical Therapy’s culture and mission will make for a strong match for continued the best quality patient care, regional growth and success.

For more information on Advanced and Preferred Physical Therapy, please visit http://www.aptclinics.com and http://www.preferredptkc.com. To learn more about Confluent Health, visit http://www.GoConfluent.com.

About Confluent Health:

Confluent Health is a Louisville, Kentucky-based private equity holding company focused on creating a healthcare system that recognizes physical and occupational therapy providers as the Best First Choice for preventing and managing musculoskeletal and movement disorders. Confluent Health offers the following management services: evidence-based practice, patient loyalty, regulatory assurance, marketing and branding, clinic operations, hiring and retention, strategy, accounting and finance, and customer service to BreakThrough Physical Therapy, El Paso Physical Therapy Specialists, Evidence In Motion, Fit For Work, Baton Rouge Physical Therapy, Capitol Physical Therapy, Lake Centre for Rehab and Rehab Therapy Works, Orthopaedic and Sports Physical Therapy, Physical Therapy Central, ProActive Physical Therapy Specialists, Pappas Physical Therapy, ProRehab Physical Therapy, Redbud Physical Therapy, RET Physical Therapy Group, SporTherapy, Tallahassee Orthopaedics and Sports Physical Therapy, and Texas Physical Therapy Specialists. Together, these companies share a common ownership team and are committed to developing a learning, purpose, and coaching culture.

Share article on social media or email:

Efficacy of Service Dogs for Veterans Living with Post-traumatic Stress


News Image

“This virtual lecture was an exciting opportunity to share the important findings that demonstrate the efficacy of service dogs for reducing PTSD symptomology in war veterans, who deserve the healing support of service dogs,” said Steven Feldman, Executive Director of HABRI.

The Human Animal Bond Research Institute (HABRI) and IDEXX held a virtual lecture on the health benefits of psychiatric service dogs for veterans with post-traumatic stress disorder (PTSD). This is the first lecture of the IDEXX Human-Animal Bond Lecture Series, which highlights impactful scientific research on the health benefits of the human-animal bond and the importance of veterinary medicine in strengthening human-animal bonds.

The Veterans Day lecture, titled The Efficacy of Service Dogs for Veterans with PTSD, featured a conversation with Marguerite E. O’Haire, PhD, Associate Professor of Human-Animal Interaction, Center for the Human-Animal Bond at Purdue University. Dr. O’Haire discussed findings and implications of her groundbreaking HABRI-funded study, Preliminary efficacy of service dogs as a complementary, therapeutic treatment for post-traumatic stress in military members, veterans and their families.

“IDEXX is proud to sponsor this lecture series which will serve as a valuable educational resource for both the general public and for the veterinary community about the science of the human-animal bond,” said Kerry Bennett, Corporate Vice President, IDEXX. “We know pet owners rely on their veterinarians to deliver scientific information about the health benefits of their pets, and when veterinarians and animal health professionals effectively communicate the science of the human-animal bond, they can strengthen bonds by encouraging compliance and improving animal care and welfare.”

Published in the Journal of Consulting and Clinical Psychology in 2018, Dr. O’Haire’s proof-of-concept study assessed the efficacy of service dogs as a complementary treatment for military members and veterans living with PTSD. Results indicate that those with a service dog exhibited significantly lower overall PTSD symptom severity, including increased overall psychological well-being; a better ability to cope with flashbacks and anxiety attacks; a lower frequency of nightmares and less overall sleep disturbance; lower overall anxiety, depression, and anger; higher levels of companionship and social reintegration; and lower levels of social isolation, in comparison to those on the waitlist to receive a service dog. The success of this study led to a large-scale National Institutes of Health (NIH) clinical trial, which is ongoing and expected to be completed in 2021.

“This virtual lecture was an exciting opportunity to share the important findings that demonstrate the efficacy of service dogs for reducing PTSD symptomology in war veterans, who deserve the healing support of service dogs,” said Steven Feldman, Executive Director of HABRI. “HABRI is grateful for IDEXX for making this lecture series possible so that veterinary health professionals and pet owners can learn more about the many ways in which the science of the human-animal bond benefits our collective health and wellness.”

The lecture remains available for viewing on-demand at http://www.habri.org/HAB-Lectures.

About HABRI

HABRI is a not-for-profit organization that maintains the world’s largest online library of human-animal bond research and information; funds innovative research projects to scientifically document the health benefits of companion animals; and informs the public about human-animal bond research and the beneficial role of companion animals in society. For more information, please visit https://www.habri.org/

About IDEXX

IDEXX Laboratories, Inc. is a member of the S&P 500® Index and is a leader in pet healthcare innovation, serving practicing veterinarians around the world with a broad range of diagnostic and information technology-based products and services. IDEXX products enhance the ability of veterinarians to provide advanced medical care, improve staff efficiency, and build more economically successful practices. IDEXX is also a worldwide leader in providing diagnostic tests and information for livestock and poultry, tests for the quality and safety of water and milk, and point-of-care and laboratory diagnostics for human medicine. For more information, please visit https://www.idexx.com/en/

###

Share article on social media or email:

ASCP and CAP Announce Laboratory Workup of Lymphoma in Adults Guideline


News Image

“The overall weakness of the evidence base suggests many research opportunities to better inform the issue dealt with in the guideline,” adds Steven Kroft, MD, ASCP co-chair of the expert panel.

The American Society for Clinical Pathology (ASCP) and the College of American Pathologists (CAP) have released a new evidence-based clinical practice guideline, “Laboratory Workup of Lymphoma in Adults,” that focuses on the pre-analytic phase of tissue handling and lymphoma diagnosis to help clinical teams improve patient care.

Recent estimates show that more than 75,000 new cases of non-Hodgkin lymphoma will be diagnosed this year in the U.S., with an additional 8,400 cases of Hodgkin lymphoma projected. Pathologists are challenged to diagnose lymphoma on samples of decreasing tissue volume, including those from fine needle aspirations and needle biopsies. Furthermore, advancements in lymphoma knowledge require clinical teams to perform a growing number of ancillary tests to differentiate specific lymphoma subtypes with complex diagnostic criteria to better optimize therapy for individual patients. This can lead to varied approaches depending on practice settings, and the new guideline provides direction and leadership to bridge the gaps.

“This guideline is an important stepping stone,” says Matthew Cheung, MD, co-chair of the guideline’s expert panel. “We can now detail areas in which well-designed prospective studies are essential to clarify the ideal specimen requirements required for modern ancillary testing techniques.”

“The overall weakness of the evidence base suggests many research opportunities to better inform the issue dealt with in the guideline,” adds Steven Kroft, MD, ASCP co-chair of the expert panel. “Many practices appear to have become standard of care without the generation of a robust evidence base.”

Developed following the standards endorsed by the National Academy of Medicine, and published jointly in the American Journal of Clinical Pathology and Archives of Pathology & Laboratory Medicine, the guideline is a collaborative effort by ASCP, the CAP, and the American Society of Hematology (ASH). Patient advocates were also included in the development of the guideline to provide non-clinical perspectives. The expert panel reviewed more than 6,000 articles from peer-reviewed literature to answer the overarching question, “What are the specimen requirements for accurate diagnosis for adult patients in whom lymphoma is suspected?”

“The lack of high-quality evidence for practices that are widely accepted was eye opening,” says Cordelia Sever, MD, FCAP, and CAP co-chair of the expert panel. “The predictive value of a set of diagnostic tests in lymphoma depends on the ultimate diagnosis, which introduces great complexity in the work up and diagnostic interpretation, unlike most other diagnostic test algorithms.”

The 13 evidence-based recommendations address the pre-analytic phase of testing, with an emphasis on specimen requirements, as well as ancillary diagnostic testing, and appropriate follow-up for safe and accurate diagnosis of indolent and aggressive histology lymphomas.

To learn more, visit http://www.ajcp.com or http://www.cap.org.

About the American Society for Clinical Pathology (ASCP)

Founded in 1922 in Chicago, ASCP unites more than 120,000 anatomic and clinical pathologists, residents and fellows, medical laboratory professionals and students to accelerate the advancement of laboratory medicine to better improve patient care through knowledge, collaboration and global community. ASCP’s mission is to provide excellence in education, certification, and advocacy on behalf of the patients, pathologists, and laboratory professionals across the globe. To learn more, visit http://www.ascp.org. Follow us on Twitter at and connect with us on Facebook.

About the College of American Pathologists (CAP)

As the world’s largest organization of board-certified pathologists and leading provider of laboratory accreditation and proficiency testing programs, the CAP serves patients, pathologists, and the public by fostering and advocating excellence in the practice of pathology and laboratory medicine worldwide. For more information, READ THE CAP ANNUAL REPORT at cap.org.

Share article on social media or email:

Neurologist and Research Pioneer in Cannabis and Psychopharmacology, Dr. Ethan Russo, Endorses Industry Leader True Terpenes


“True Terpenes is a prime example of a company dedicated to the science of terpenes and terpenoids and I’ve been thrilled to continue my work with their products and team over the past few years as it aligns with and enhances my personal research,” said Dr. Ethan Russo.

Dr. Ethan Russo, a scientific luminary in cannabis research, has officially endorsed True Terpenes based on the company’s excellence in terpene innovation. Dr. Russo’s research on the entourage effect, where the benefits of medical cannabis can be enhanced when combined with terpenes, is the backbone of the terpenes industry. His support speaks to True Terpenes’ high-quality products, rigorous testing standards and influence in cannabis.

“True Terpenes is a prime example of a company dedicated to the science of terpenes and terpenoids and I’ve been thrilled to continue my work with their products and team over the past few years as it aligns with and enhances my personal research,” said Dr. Ethan Russo. “The company’s products are particularly attractive for me because of their purity, high standard of manufacturing, and commitment to quality assurance, which is not standard across the industry.”

True Terpenes stands out for its botanically derived terpenes that are closer to terpenes found naturally and don’t possess additional toxicities.

“We are incredibly grateful for Dr. Ethan Russo’s commitment to True Terpenes, through his research, seat on the Scientific Advisory Board, and premier blends,” said Chris Campagna, CEO of True Terpenes. “Without the decades of groundbreaking research by Dr. Russo, the cannabis and terpene industries and communities would not be where they are today. We look forward to a long and fruitful partnership alongside Dr. Russo.”

Dr. Russo is a founding member of True Terpenes’ Scientific Advisory Board, created in May 2020. This summer True Terpenes and Dr. Russo launched an exclusive line of effect-based terpene, “Terpology by Dr. Ethan Russo,” to bring scientific credibility to the experience of terpenes.

About True Terpenes

True Terpenes, a fully owned subsidiary of True Companies, is the industry-leading producer of effects-based, GMP/ISO/FSSC-certified terpenes and terpenoids blends. Using ultra-refined botanical terpenes and other aromatic compounds, the custom terpene blends are used for beverage, cannabis, cosmetic, food, industrial and pharmaceutical products. The company uses advanced scientific analysis to identify terpenes and other compounds in the cannabis plant for recreation by utilizing other botanicals and hemp-derived ingredients. This allows companies in various industries looking to leverage cannabis flavors and effects with a scalable, standardized, and worldwide legal solution.

Disclaimer

Any forward-looking statements included in this document are made as of the date of this document and Corporation disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Although management of the Corporation believes that the expectations represented in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct.

Media Contact:

Marino.

Samantha Qualls, Senior Director

TrueTerpenes@marinopr.com

Share article on social media or email:

ISPE Publishes ISPE GAMP® RDI Good Practice Guide: Data Integrity by Design


ISPE GAMP® RDI Good Practice Guide: Data Integrity by Design

As with all GAMP® Guides, the content has been written by active industry personnel, passionate about patient safety and improvements to the regulated industry, who have experienced the problems, the issues, and the pain in their day jobs.

The International Society for Pharmaceutical Engineering (ISPE) announced the release of its latest Guide, ISPE GAMP® RDI Good Practice Guide: Data Integrity by Design. This Guide was written by a group of experts and reviewed by regulators and practitioners in the field, and supports a holistic data integrity approach using data governance and knowledge management activities.

“Data Integrity by Design is the concept that data integrity must be incorporated from the initial planning of a business process through to the implementation, operation and retirement of computerized systems supporting that business process,” said Lorrie Vuolo-Schuessler, Guide Co-Lead, Senior Director Computer Systems Quality and Data Integrity, Syneos Health. “It promotes the application of critical thinking to identify how data flows through the business process and to proactively assess and mitigate risks across both the system and data lifecycles. It emphasizes data integrity as foundational to protecting patient safety and product quality.”

This Guide provides a bridge between the system lifecycle approach defined in ISPE GAMP® 5: A Risk-Based Approach to Compliant GxP Computerized Systems, and the data lifecycle approach in the ISPE GAMP® Guide: Records and Data Integrity. Data integrity can only be achieved when both lifecycle approaches are adopted, understood, and actively managed.

Several new areas are covered in this Guide’s appendices, including knowledge management, instrument devices and an appendix on Computer Software Assurance (CSA) that details CSA key concepts and provides illustrative case studies.

“Computer Software Assurance was born from US FDA CDRH’s Case for Quality which treats compliance attainment as the baseline and promotes the inclusion of critical-to-quality practices that result in improved quality outcomes,” said Charlie Wakeham, Guide Co-Lead, APAC GxP Compliance Manager, Waters Corporation. “An industry team was formed, and work begun on the development of an FDA Draft guidance to apply this paradigm to Computerized System Validation (CSV). In an industry first, members of this CSA team have collaborated closely with GAMP subject matter experts to create an appendix to the Data Integrity by Design Guide detailing the key concepts of CSA and providing illustrative case study examples of its application.”

“As with all GAMP® Guides, the content has been written by active industry personnel, passionate about patient safety and improvements to the regulated industry, who have experienced the problems, the issues, and the pain in their day jobs,” said Jim Henderson, Guide Co-Lead, Business/Computer System QA, Eli Lilly and Company. “This elicits a level of practicality and detail in the guidance that allows the reader to readily apply the guidance to their own organizations.”

Get an idea of what this Guide has to offer by viewing the table of contents.

Purchase the ISPE GAMP® RDI Good Practice Guide: Data Integrity by Design online, available at ISPE.org/Publications/Guidance-Documents, among ISPE’s other detailed education resources on a variety of industry topics.

About ISPE

The International Society for Pharmaceutical Engineering (ISPE) is a not-for-profit association serving its members through leading scientific, technical, and regulatory advancement across the entire pharmaceutical lifecycle. The 18,000 members of ISPE are building solutions in the development and manufacture of safe, effective pharmaceutical and biologic medicines, and medical delivery devices in more than 90 countries around the world. Founded in 1980, ISPE has its worldwide headquarters and training center in North Bethesda, Maryland, USA, and its operations center in Tampa, Florida, USA. Visit ISPE.org for more information.

For more information, contact:

Amy Henry

Marketing Communications Manager

International Society for Pharmaceutical Engineering (ISPE)

Email: ahenry@ispe.org

ISPE.org

Share article on social media or email: